Infliximab in drug-naïve patients with failed ileorectal anastomosis for crohn's disease: A new chance for sparing the rectum?

European Surgical Research

Volumn 46, Issue 4, 2011, Pages 163-168

  Sciaudone, G ^a   Pellino, G ^a   Riegler, G ^a   Selvaggi, F ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Crohn's disease; Ileorectal anastomosis; Infliximab; Quality of life; Rectal sparing

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; HYDROCORTISONE; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORECTAL DISEASE; CROHN DISEASE; DEFECATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; ILEORECTAL ANASTOMOSIS; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FUNCTION; LONG TERM CARE; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM RESECTION; RECURRENT DISEASE; TOTAL COLON RESECTION; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANASTOMOSIS, SURGICAL; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; ILEUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECTUM; YOUNG ADULT;

EID: 79953168475     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000324398     Document Type: Article

References (38)

1. Farmer RG, Hawk WA, Turnbull RB Jr: Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 627-635.
2. Lockhart-Mummery HE: Crohn's disease: anal lesions. Dis Colon Rectum 1973; 18: 200.
3. Lennard-Jones JE, Ritchie JK, Zohrab WJ: Proctocolitis and Crohn's disease of the colon: a comparison of the clinical course. Gut 1976; 17: 477-482.
4. Wolff BG, Culp CE, Beart RW Jr, Ilstrup DM, Ready RL: Anorectal Crohn's disease. A long-term perspective. Dis Colon Rectum 1985; 28:709-711. (Pubitemid 16236872)
5. Williams JG, Wong WD, Rothenberger DA, Goldberg SM: Recurrence of Crohn's disease after resection. Br J Surg 1991; 78:10-19.
6. Tekkis PP, Purkayastha S, Lanitis S, Athanasiou T, Heriot AG, Orchard TR, Nicholls RJ, Darzi AW: A comparison of segmental vs. subtotal/total colectomy for colonic Crohn's disease: a meta-analysis. Colorectal Dis 2006; 8: 82-90. (Pubitemid 43372454)
7. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD: Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease. A single center experience. Dis Colon Rectum 2003; 46:577-583. (Pubitemid 36576412)
8. Present DH, Rutgeers P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Eng J Med 1999; 340: 1398-1405. (Pubitemid 29205403)
9. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rut-geerts P, ACCENT I Study Group: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549. (Pubitemid 34621118)
10. Scribano ML, Prantera C: Review article: medical treatment of active Crohn's disease. A liment Farmacol Ther 2002; 16: 35-39. (Pubitemid 34595616)
11. Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M: Review article: the management of refractory Crohn's disease. Aliment Farmacol Ther 2002; 16:40-47. (Pubitemid 34595617)
12. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee: AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125:1508-1530.
13. Hyder SA, Travis SPL, Jewell DP, McC Mortensen NJ, George BD: Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49:1837-1841. (Pubitemid 44853440)
14. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to inf li ximab in Crohn's disease. Gut 2007; 56: 1226-1231. (Pubitemid 47300423)
15. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulising Crohn's disease. N Engl J Med 2004; 350: 876-885. (Pubitemid 38252535)
16. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P: Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut 2009; 58: 492-500.
17. Fidder HH, Schnitzler F, Ferrante M, Norman M, Katsanos K, Segaert S, Van Assche G, Vermeire S, Rutgeerts P: Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2009; 58: 501-508.
18. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C: A new measure of health status for clinical trials in inflammatory bowel disease. Gastro-enterology 1989; 96:804-810. (Pubitemid 19057603)
19. Buchmann P, Waterman IT, Keighley MRB, et al: The prognosis of ileorectal anastomosis in Crohn's disease. Br J Surg 1981; 68:7-10. (Pubitemid 11218842)
20. Ambrose NS, Keighley MR, Alexander-Williams J, Allan RN: Clinical impact of colec-tomy and ileorectal anastomosis in the management of Crohn's disease. Gut 1984; 25: 223-227. (Pubitemid 14127879)
21. Longo WE, Oakley JR, Lavery IC, Church JM, Fazio VW: Outcome of ileorectal anastomosis for Crohn's colitis. Dis Colon Rectum 1992; 35: 106 6-1071.
22. Rieger N, Collopy B, Fink R, Mackay J, Woods R, Keck J: Total colectomy for Crohn's disease. Aust NZ J Surg 1999; 69:28-30. (Pubitemid 29051357)
23. Yamamoto T, Keighley MR B: Fate of t he rectum and ileal recurrence rates after total col-ectomy for Crohn's disease. World J Surg 2002; 24:125-129.
24. Cattan P, Bonhomme N, Panis Y, Lémann M, Coffin B, Bouhnik Y, Allez M, Sarfati E, Valleur P: Fate of the rectum in patients undergoing total colectomy for Crohn's disease. Br J Surg 2002; 89:454-459.
25. Elton C, Makin G, Hitos K, Cohen CR: Mortality, morbidity and functional outcome after ileorectal anastomosis. Br J Surg 2003; 90: 59-65. (Pubitemid 37040972)
26. Keighley MR, Buchmann P, Lee JR: Assessment of anorecta l f unct ion in selection of patients for ileorectal anastomosis in Crohn's colitis. Gut 1982; 23: 102-107. (Pubitemid 12171865)
27. Weaver RM, Keighley MR: Measurement of rectal capacity in the assessment of patients for colectomy and ileorectal anastomosis in Crohn's colitis. Dis Colon Rectum 1986; 29: 443-445. (Pubitemid 16057732)
28. Mortensen NJ, Ritchie JK, Hawley PR, Todd IP, Lennard-Jones JE: Surgery for acute Crohn's colitis: results and long-term follow-up. Br J Surg 1984; 71: 783-784. (Pubitemid 14041886)
29. Sorrentino D, Terrosu G, Avellini C, Beltra-mi CA, Bresadola V, Toso F: Prevention of postoperative recurrence of Crohn's disease by infliximab. Eur J Gastroenterol Hepatol 2006; 18: 457-459.
30. Rutgeerts P, D'Haens G, Targan S: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gas-troenterolog y 1999; 117: 761-769. (Pubitemid 29468216)
31. Sands B, Van Deventer S, Bernstein C: Long-term treatment of fistulising Crohn's disease: response to infliximab in the ACCENT II trial through 54 weeks (abstract). Gastro-enterology 2002; 122:A81.
32. Poritz LS, Rowe WA, Koltun WA: Remicade does not abolish the need for surgery in fis-tulising Crohn's disease. Dis Colon Rectum 2002; 45:771-775. (Pubitemid 34602491)
33. Regueiro M, Mardini H: Treatment of peri-anal fistulising Crohn's disease with inflix-imab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9: 98-103. (Pubitemid 36367318)
34. Rutgeerts P, Van Assche G, Vermeire S: Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006; 23: 451-463. (Pubitemid 43381999)
35. Rubenstein JH, Chong RY, Cohen RD: Inf-liximab decreases resource use among patients with Crohn's disease. J Clin Gastroen-terol 2002; 35: 151-156. (Pubitemid 34815854)
36. Hanauer S, Schreiber S, Bao W, Bala M, Keenan G, Olson A, Rutgeerts P: ACCENT I trial: infliximab response rates over 30 weeks. Am J Gastroenterol 2001; 96:S302.
37. Sorrentino D, Terrosu G, Avellini C, Maiero S: Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007; 16 7: 1804-1807. (Pubitemid 47403070)
38. Cassinotti A, Travis S: Incidence and clinical significance of immunogenicity to inflix-imab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15:1264-1275.